Physician profile
Michael Everett Conner
NPI 1336644459
$3,240.96
in general payments reported to CMS, 2019-2025
22 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $781 · 2023: $735 · 2024: $464 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.64 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.87 | 2023-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $472.98 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $431.61 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $269.07 | 2022-2025 | Endoflip |
| Celgene Corporation | $229.92 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $189.92 | 2025 | Ibsrela |
| W. L. Gore & Associates, INC. | $134.89 | 2022 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Madrigal Pharmaceuticals | $121.11 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.05 | 2022-2024 | Xifaxan |
| Genzyme Corporation | $112.20 | 2025 | |
| Mirum Pharmaceuticals, INC. | $107.41 | 2023-2024 | Livmarli |
| Capsovision, INC. | $62.08 | 2023-2024 | Capsocam Plus |
| Gilead Sciences, INC. | $45.92 | 2025 | |
| Blueprint Medicines Corporation | $45.23 | 2023-2024 | Ayvakit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.45 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $39.10 | 2022-2023 | Ocaliva |
| Lilly USA, LLC | $37.20 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $28.37 | 2025 | Dupixent |
| Organon LLC | $23.63 | 2025 | Hadlima, Renflexis |
| Ferring Pharmaceuticals INC. | $13.97 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $10.99 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.